# Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study

> **NCT02034838** · PHASE1 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 12 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** atazanavir 300mg boosted with ritonavir 50 mg

## Key facts

- **NCT ID:** NCT02034838
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-11
- **Final completion:** 2015-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034838, "Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02034838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*